Fatal septic shock due to disseminated coccidioidomycosis: a case series and review of the literature
BMC Infectious Diseases volume 23, Article number: 430 (2023)
Coccidioidomycosis is a fungal infection endemic to the southwestern United States and regions of Latin America. Disseminated disease occurs in < 1% of cases. Septic shock is even rarer, with high mortality despite therapy.
We describe two cases of coccidioidal septic shock. Both patients were older men of Filipino ancestry presenting with respiratory failure and vasopressor-dependent shock. Antifungal drugs were initiated after failure to improve with empiric antibiotics; in both, Coccidioides was isolated from respiratory cultures. Despite aggressive care, both patients ultimately died of their infections. We provide a review of the published literature on this topic.
Most of the 33 reported cases of coccidioidal septic shock occurred in men (88%) of non-white race and ethnicity (78%). The overall mortality rate was 76%. All survivors received amphotericin B as part of their treatment. Coccidioidomycosis-related septic shock is a rare disease with poor outcomes; delays in diagnosis and treatment are common. Improved diagnostic testing for coccidioidomycosis could enhance recognition of this disease in the future. Although data are limited, early treatment with amphotericin B in cases of coccidioidal septic shock may reduce mortality.
Coccidioidomycosis is a fungal infection endemic to the southwestern United States and regions of Latin America . Most infections are confined to the lungs, but disseminated disease occurs in < 1% of cases and leads to significant morbidity and potential mortality . Septic shock due to coccidioidomycosis is a rare with a high associated risk of death. Procalcitonin (PCT) is not typically elevated in non-critically ill patients with coccidioidomycosis ; it is unclear if this applies to very sick patients. Here, we describe two cases of coccidioidomycosis complicated by septic shock from our hospital and include a review of the literature.
Case report 1
A 70-year-old Filipino man with type 2 diabetes mellitus presented to the emergency department (ED) with complaints of dyspnea, cough, and malaise. He resided in southern California and had no recent travel history. After initial evaluation, he was diagnosed with community-acquired pneumonia and was prescribed moxifloxacin 400 mg by mouth daily for an anticipated seven day course. He failed to improve on moxifloxacin and returned to the ED two days later with worsening cough. In the ED, the patient was tachycardic, tachypneic, and hypoxemic. He was admitted to the hospital and received ceftriaxone 1 g intravenously (IV) every 24 h and azithromycin 500 mg daily by mouth. Computed tomography of the chest demonstrated a progressively worsening multilobar pneumonia as well as a left pleural effusion (Fig. 1). Tube thoracostomy was performed, demonstrating an exudative effusion with lymphocytes but no visible organisms on Gram stain.
On the fourth hospital day, he became increasingly tachypneic and hypoxemic, requiring transfer to the intensive care unit (ICU) where he underwent endotracheal intubation and mechanical ventilation. Despite broad-spectrum antibacterial therapy, his hemodynamics continued to worsen, requiring escalating levels of vasopressor support. Anuria and refractory acidemia developed over the next 48 h, and continuous renal replacement therapy (CRRT) was initiated. Sputum cultures from the time of intubation demonstrated small fungal colonies. On the sixth hospital day, serologic testing for Coccidioides returned as positive, and fluconazole 800 mg IV daily and caspofungin 70 mg IV daily were started. The aforementioned sputum isolate was ultimately confirmed as Coccidioides immitis. The patient’s oxygenation and hemodynamics initially improved on antifungal therapy. On the ninth hospital day, however, he developed ventricular fibrillation and cardiac arrest; attempts at resuscitation were unsuccessful, and he died thereafter,
A postmortem examination showed a diffuse, thick white purulence present throughout the lungs bilaterally, most significantly involving the left lower lobe. Microscopic examination of the lung tissue demonstrated necrosis and inflammation, as well as Coccidioides spherules and spores (Fig. 2). Additionally, spherules were identified microscopically in the liver and spleen.
Case report 2
A 74-year-old Filipino man developed a dry cough 3 weeks prior to presentation. He had no overt history of desert or dust exposure other than residence in southern California. He was treated with a 5-day course of oral azithromycin without improvement. Subsequently, his family noted a progressive decline in his alertness and energy level, accompanied by intermittent low-grade fevers with poor appetite and weight loss. Two days prior to presentation, the patient’s cognitive function declined dramatically. He stopped responding to questions and became incontinent of urine. He was brought to the ED by his family, where he was febrile at 39.1 °C, tachycardic (134 beats/minute), tachypneic (32 breaths/minute), but normotensive (123/70 mmHg). A physical examination was notable for inspiratory crackles in the left middle lung field. The patient’s initial PCT was 1.73 µg/L (normal range < 0.25 µg/L). Chest radiography demonstrated a cavitary lesion in the left upper lobe (Fig. 3). He was admitted to the ICU; vancomycin 15 mg/kg IV every 12 h and piperacillin-tazobactam 4.5 g IV every eight hours via extended infusion were administered empirically.
His condition worsened on the second hospital day, requiring vasopressor support and endotracheal intubation. He developed an absolute peripheral eosinophil count of 6400 cells/mL and a rising PCT of 2.4 µg/L. His shock worsened, with the development of acute kidney injury requiring CRRT. PCT increased further to 400 µg/L. Culture of bronchoalveolar lavage fluid was notable for yeast forms. The patient was first started on fluconazole 800 mg IV daily for empiric treatment of coccidioidal pneumonia and then switched quickly to liposomal amphotericin B 5 mg/kg IV every 24 h. Unfortunately, he failed to improve over the next 2 days and, after a family discussion, was compassionately extubated on hospital day 6. Following his death, the bronchoalveolar lavage cultures were finalized as Coccidioides immitis; his anti-Coccidioides complement fixation titer was positive at 1:4.
Literature review and discussion
We performed a MEDLINE and Google Scholar search using the terms “coccidioidomycosis”, “Coccidioides”, “sepsis”, and “septic shock”. English and Spanish-language articles and conference abstracts were included. Manuscripts so identified were then reviewed by the authors. Cases were included if the patient had a positive confirmed diagnosis of coccidioidomycosis (based on culture, serology, or histopathology) and vasopressor-dependent shock without a compelling alternate cause (e.g., concomitant bacteremia). Data on patient age, gender, ethnicity, comorbidities, antifungal and immunomodulatory therapy administered, and outcome were tabulated. We also screened the identified manuscripts for reported PCT values.
Written informed consent was obtained from the families of the two patients included in this report. This review was approved by the Institutional Review Board at Naval Medical Center San Diego in accordance with all relevant U.S. Federal regulations for the conduct of biomedical research. None of the authors reported any potential conflicts of interest in relation to the current work. No funding was received for this work.
We identified 20 reports describing 33 patients with vasopressor-dependent septic shock due to Coccidioides infection since 1993 (Table 1), including the 2 patients described here. Of these patients, 29/33 (88%) were male, and 25/33 (76%) died from their illnesses. Of those with ethnicity, 12/26 (46%) were Latino, 6/26 (23%) of African descent, 5/26 (19%) Asian-Pacific Islander, and 3/26 White (12%). All but 2 were adults, with a median age of 58 years. Of the 33 patients, 24 (73%) had reported comorbid conditions, including human immunodeficiency virus (HIV) infection (5/24), solid organ transplantation (4/24), and diabetes mellitus (6/24).
Mortality was high across all reported cases. Of note, 22 patients received amphotericin B, including all of the survivors. Among those patients treated with amphotericin B, 13/22 died compared with 12/12 treated with other agents or not treated at all. Of the 3 cases with reported PCT levels, all were elevated (Wisniewski: > 400 µg/L; Aduroja: 6.1 µg/L; Berenji: > 20 µg/L).
The two cases and prior reported cases suggest several key points for the management of patients with Coccidioides sepsis. Coccidioides sepsis is rare but may be underdiagnosed because its rarity precluded clinicians from suspecting the diagnosis. As such, clinicians must maintain a degree of suspicion if a patient has been exposed to an endemic area, especially with risk factors for complicated disease. A clinical trial of fluconazole as a component of therapy for acute community-acquired pneumonia in coccidioidomycosis-endemic regions was halted due to slow enrollment, limiting our ability to assess the impact of early antifungal therapy in patients at risk for severe disease . Regardless, diagnostic evaluation for Coccidioides, including serologic testing and careful examination of respiratory cultures, seems prudent for at-risk patients who are not improving on empiric antibacterial therapy. Recent years have seen an expansion in the geographic distribution of coccidioidomycosis in North America, with locally-acquired infections identified outside of its historic endemic zones, suggesting that clinicians may need to maintain a higher index of suspicion . Increased use of sputum Gram stain and culture in patients presenting to EDs with community-acquired pneumonia may be useful in helping identify seriously-ill patients more rapidly, given that early coccidioidal growth may be seen within 2–3 days.
Coccidioides septic shock carries a high mortality risk, with as many as 3 of every 4 patients succumbing to the disease. Though this could be due to multiple factors, delays in diagnosis and early aggressive therapy are likely among them. In the 33 patients in the literature, treatment with amphotericin B appears to correlate with better survival. Although no high-quality evidence exists on this topic, the 2016 Infectious Diseases Society of America guideline for the management of coccidioidomycosis recommends the use of amphotericin B in severe disease . Liposomal amphotericin B (LAmB) was approved for use in the United States by the Food and Drug Administration (FDA) in 1997; patients treated prior to 1997 in our case series presumably received amphotericin B deoxycholate, whereas cases treated later received predominantly lipid formulations (LAmB or amphotericin B lipid complex). There are insufficient data to state whether lipid formulations of amphotericin B have an advantage in treating severe coccidioidomycosis. We acknowledge the risk of publication bias in the reported mortality of this series, although the overall mortality of coccidioidal sepsis is likely very high regardless.
We caution against reliance on PCT to exclude coccidioidomycosis in a patient in septic shock. In a 2014 study of 20 patients with coccidioidomycosis, none of whom were critically ill, the median PCT level was 0.05 µg/L . Although these data suggest that PCT elevations are not a typical feature of Coccidioides infection, this may not be the case for the minority of patients presenting with vasopressor-dependent shock. Elevated serum PCT levels may reflect severity of illness rather than serve as a differential marker of bacterial versus nonbacterial infections. This phenomenon has been observed other severe nonbacterial diseases, to include COVID-19, influenza, and candidemia [25,26,27,28]. As such, PCT may not provide sufficient specificity to determine bacterial versus non-bacterial diseases in life-threatening infections, including coccidioidomycosis.
Septic shock due to Coccidioides infection carries a high risk of death. Delay in diagnosis is common, due to the rarity of the disease and the challenges inherent to its diagnosis. High procalcitonin levels appear to occur in coccidioidal sepsis and may reflect severity of illness, rather than suggesting more common diagnoses such as bacterial sepsis. Improved diagnostic testing for coccidioidomycosis could enhance recognition of this disease in the future. Although data are limited, early treatment with amphotericin B in cases of coccidioidal septic shock may reduce mortality.
Availability and data and materials
The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.
Coronavirus disease 2019
Continuous renal replacement therapy
Food and Drug Administration (United States)
Intensive care unit
Liposomal amphotericin B
Brown J, Benedict K, Park BJ. Thompson GR Coccidioidomycosis: epidemiology. Clin Epidemiol. 2013;5:185–97. https://doi.org/10.2147/CLEP.S34434.
Stevens A. Coccidioidomycosis. N Engl J Med. 1995;332:1077–82. https://doi.org/10.1056/NEJM199504203321607.
Sakata KK, Grys TE, Chang YH, Vikram HR, Blair JE. Serum procalcitonin levels in patients with primary pulmonary coccidioidomycosis. Ann Am Thorac Soc. 2014;11(8):1239–43. https://doi.org/10.1513/AnnalsATS.201404-180BC.
Lopez AM, Williams PL, Ampel NM. Acute pulmonary coccidioidomycosis mimicking bacterial pneumonia and septic shock: a report of two cases. Am J Med. 1993;95(2):236–9. https://doi.org/10.1016/0002-9343(93)90267-s.
Arsura EL, Bellinghausen PL, Kilgore WB, Abraham JJ, Johnson RH. Septic shock in coccidioidomycosis. Crit Care Med. 1998;26(1):62–5. https://doi.org/10.1097/00003246-199801000-00017.
Cha JM, Jung S, Bahng HS, Lim CM, Han DJ, Woo JH, Koh Y. Multi-organ failure caused by reactivated coccidioidomycosis without dissemination in a patient with renal transplantation. Respirology. 2000;5(1):87–90. https://doi.org/10.1046/j.1440-1843.2000.00232.x.
Shibli M, Ghassibi J, Hajal R, O’Sullivan M. Adjunctive corticosteroids therapy in acute respiratory distress syndrome owing to disseminated coccidioidomycosis. Crit Care Med. 2002;30(8):1896–8. https://doi.org/10.1097/00003246-200208000-00037.
Visbal AL, DeValeria PA, Blair JE, Zarka MA, Lanza LA. Coccidioidal pericarditis: implications of surgical treatment in the elderly. Ann Thorac Surg. 2003;75(4):1328–30. https://doi.org/10.1016/s0003-4975(02)04621-0.
Crum NF, Groff HL, Parrish JS, Ring W. A novel use for drotrecogin alfa (activated): successful treatment of septic shock associated with coccidioidomycosis. Clin Infect Dis. 2004;39(11):e122–3. https://doi.org/10.1086/425918.
Rempe S, Sachdev MS, Bhakta R, Pineda-Roman M, Vaz A, Carlson RW. Coccidioides immitis fungemia: clinical features and survival in 33 adult patients. Heart Lung. 2007;36(1):64–71. https://doi.org/10.1016/j.hrtlng.2006.10.001.
Desai NR, McGoey R, Troxclair D, Simeone F, Palomino J. Coccidioidomycosis in nonendemic area: case series and review of literature. J La State Med Soc. 2010;162(2):97–103.
Blodget E, Geiseler PJ, Larsen RA, Stapfer M, Qazi Y, Petrovic LM. Donor-derived Coccidioides immitis fungemia in solid organ transplant recipients. Transpl Infect Dis. 2012;14(3):305–10. https://doi.org/10.1111/j.1399-3062.2011.00698.x. Epub 2011 Dec 18.
Ramsi M, Alvira C, Purohit P, Cornfield D. Haemophagocytic lymphohistiocytosis associated with coccidiomycosis. BMJ Case Rep. 2014;2014:bcr2014205681. https://doi.org/10.1136/bcr-2014-205681.
El Dib NA, Eldessouky NM, El Sherbini SA, Seleem HM, Algebaly HF. Disseminated coccidioidomycosis in a 5-year-old Sudanese boy. J Trop Pediatr. 2014;60(3):260–3. https://doi.org/10.1093/tropej/fmu002.
Shamsid-Deen N, Sinha A, Whiting T. An unusual case of severe ards incited by extrapulmonary coccidioidomycosis requiring extracorporeal membrane oxygenation in an immunocompetent host. In: C52. Critical care case reports: good vibrations-mechanical ventilation from NIV To ECMO. American Thoracic Society; 2018. p. A5247.
Eltayeb M, Asad S, Malik A, Cao Y, Yu WY, Hong A. Fluconazole non susceptible disseminated coccidioidomycosis in a critically Ill patient without known immunosuppression. In: D59. Fungal infection case reports. American Thoracic Society; 2019. p. A6871.
Berenji N, Birdwell AL, Anzueto A. Valley Fever in South Texas. In D48. Critical care case reports: infection and sepsis II. American Thoracic Society; 2019. p. A6624.
Chang MR, Chopra N, Beenhouwer D, Goetz MB, Hoo GWS. Corticosteroids in the Management of Severe Coccidioidomycosis. Am J Med. 2019;132(1):110–3. https://doi.org/10.1016/j.amjmed.2018.09.020.
Gulati S, Jiramethee N. Acute pulmonary coccidioidomycosis presenting as septic shock. In: D46. Critical care case reports: infection and sepsis I. American Thoracic Society; 2020. p. A6914.
Tandon AO, Saeed Z, Chu G, GarciaOrr R, Ardiles T, Uppalapu S, Whiting T. Corticosteroid use for acute respiratory distress syndrome due to refractory disseminated coccidioidomycosis. In: D47. Critical care case reports: infection and sepsis II. American Thoracic Society; 2020. p. A6948.
Aduroja O, Okudo J, Padilla A. Disseminated coccidioidomycosis presenting as septic shock with multiorgan failure. Case Rep Infect Dis. 2021;2021:8837493. https://doi.org/10.1155/2021/8837493.
Messina JA, Maziarz EK, Galgiani J, et al. A randomized, double-blind, placebo-controlled clinical trial of fluconazole as early empiric treatment of coccidioidomycosis pneumonia (Valley Fever) in adults presenting with community-acquired pneumonia in endemic areas (FLEET-Valley Fever). Contemp Clin Trials Commun. 2021;24:100851.
Mazi PB, Sahrmann JM, Olsen MA, Coler-Reilly A, Rauseo AM, Pullen M, et al. The geographic distribution of dimorphic mycoses in the United States for the modern era. Clin Infect Dis. 2023;76(7):1295–301. https://doi.org/10.1093/cid/ciac882.
Galgiani JN, Ampel NM, Blair JE, et al. 2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis. Clin Infect Dis. 2016;63(6):e112-146. https://doi.org/10.1093/cid/ciw360.
Tong-Minh K, van der Does Y, Engelen S, et al. High procalcitonin levels associated with increased intensive care unit admission and mortality in patients with a COVID-19 infection in the emergency department. BMC Infect Dis. 2022;22(1):165. https://doi.org/10.1186/s12879-022-07144-5.
Gautam S, Cohen AJ, Stahl Y, et al. Severe respiratory viral infection induces procalcitonin in the absence of bacterial pneumonia. Thorax. 2020;75(11):974–81. https://doi.org/10.1136/thoraxjnl-2020-214896.
Cortegiani A, Misseri G, Ippolito M, et al. Procalcitonin levels in candidemia versus bacteremia: a systematic review. Crit Care. 2019;23(1):190. https://doi.org/10.1186/s13054-019-2481-y.
Carbonell R, Moreno G, Martin-Loeches I, et al. Prognostic value of procalcitonin and C-Reactive Protein in 1608 Critically Ill patients with severe influenza pneumonia. Antibiotics (Basel). 2021;10(4):350. https://doi.org/10.3390/antibiotics10040350.
We wish to thank the families of the patients described in this report for the opportunity to participate in their loved ones’ care.
Several of the authors (PW, IM, CA, JE, EE) are U.S. military service members. This work was prepared as part of their official duties. Title 17, U.S.C. §105 provides that copyright protection under this title is not available for any work of the U.S. Government. Title 17, U.S.C. §101 defines a U.S. Government work as work prepared by a military service member or employee of the U.S. Government as part of that person’s official duties. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of the Army, Uniformed Services University of the Health Sciences, Department of Defense, nor the U.S. Government.
No funding of any sort was received for this work.
Ethics approval and consent to publication
This review was approved by the Institutional Review Board at Naval Medical Center San Diego in accordance with all relevant U.S. Federal regulations for the conduct of biomedical research.
Consent for publication
Written informed consent was obtained from the families of the two patients included in this report.
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Wisniewski, P., McCool, I., Walsh, J.C. et al. Fatal septic shock due to disseminated coccidioidomycosis: a case series and review of the literature. BMC Infect Dis 23, 430 (2023). https://doi.org/10.1186/s12879-023-08379-6